Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Humira, Rituxan Top List of U.S. Drugs with Biggest Price Increases

Caroline Humer  |  

Humira’s net price increase over 2017 and 2018 added $1.8 billion in spending, while Rituxan added $806 million, the report said.

Reporting by Caroline Humer; Editing by Richard Chang and Bill Berkrot

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Institute for Clinical and Economic Review. News release: ICER identifies costliest U.S. drug price hikes that are not supported by new clinical evidence. 2019 Oct 8.
  2. Institute for Clinical and Economic Review. Unsupported price increase report: 2019 assessment. 2019 Oct 8.

Related Articles

    Major Drugmakers Push Back in U.S. Price Debate

    SAN FRANCISCO (Reuters)—With a backlash brewing over the price of medicines in the U.S., drugmakers are pushing back with a new message: Most people don’t pay retail. Top executives from Eli Lilly and Co, Merck & Co and Biogen Inc. said in interviews with Reuters this week that the media focus on retail, or “list…

    Opinion: Help Bring Drug Prices Down

    I read with interest the articles in the June issue of The Rheumatologist pertaining to high drug costs. Simon Helfgott rheuminated on it, and Susan Bernstein, a medical journalist, wrote a two-page article titled “Concerns About Cost.” Both articles were thoughtful summaries of a complex issue, putting large question marks over both initial prices and…